IL300245A - Anti-connexin antibody formulations - Google Patents
Anti-connexin antibody formulationsInfo
- Publication number
- IL300245A IL300245A IL300245A IL30024523A IL300245A IL 300245 A IL300245 A IL 300245A IL 300245 A IL300245 A IL 300245A IL 30024523 A IL30024523 A IL 30024523A IL 300245 A IL300245 A IL 300245A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- formulation
- pharmaceutical formulation
- seq
- histidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059502P | 2020-07-31 | 2020-07-31 | |
| PCT/US2021/044043 WO2022026914A1 (en) | 2020-07-31 | 2021-07-30 | Anti-connexin antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300245A true IL300245A (en) | 2023-03-01 |
Family
ID=80002768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300245A IL300245A (en) | 2020-07-31 | 2021-07-30 | Anti-connexin antibody formulations |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11912764B2 (https=) |
| EP (1) | EP4188544A4 (https=) |
| JP (1) | JP2023537316A (https=) |
| KR (1) | KR20230042744A (https=) |
| CN (1) | CN116234576A (https=) |
| AU (1) | AU2021316119A1 (https=) |
| CA (1) | CA3190474A1 (https=) |
| IL (1) | IL300245A (https=) |
| WO (1) | WO2022026914A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095897A1 (en) * | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| WO2022026914A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| US20250277017A1 (en) * | 2022-04-29 | 2025-09-04 | Board Of Regents, The University Of Texas System | Compositions and methods for treating eye diseases |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
| WO2025038635A1 (en) * | 2023-08-14 | 2025-02-20 | Alamab Therapeutics, Inc. | Method of treating stroke |
| US20260103512A1 (en) * | 2024-05-24 | 2026-04-16 | Alamab Therapeutics, Inc. | Method of treating bone cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073629B1 (ko) | 2005-02-03 | 2020-02-05 | 코다 테라퓨틱스 (엔지) 리미티드 | 항-코넥신 화합물 및 그의 용도 |
| EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| US20110223204A1 (en) | 2008-06-04 | 2011-09-15 | Bradford J Duft | Treatment of pain with gap junction modulation compounds |
| MX2011009312A (es) * | 2009-03-06 | 2012-02-29 | Medimmune Llc | Formulaciones de anticuerpos humanizados anti-cd19. |
| CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
| CN114621346B (zh) | 2013-08-21 | 2025-06-10 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| US20190010224A1 (en) * | 2015-12-22 | 2019-01-10 | Merck Sharp & Dohme Corp. | Formulations of engineered anti-il-10 antibodies |
| EP3419599A4 (en) * | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| WO2017147561A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF |
| WO2017190152A1 (en) | 2016-04-29 | 2017-11-02 | Ocunexus Therapeutics, Inc. | Sustained release drug delivery devices |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP2020531523A (ja) * | 2017-08-25 | 2020-11-05 | オメロス コーポレーション | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
| CA3095897A1 (en) | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| US11274150B2 (en) * | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| KR20220113355A (ko) * | 2019-10-02 | 2022-08-12 | 알라맵 테라퓨틱스, 인크. | 항-코넥신 항체 제제 |
| WO2022026914A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
-
2021
- 2021-07-30 WO PCT/US2021/044043 patent/WO2022026914A1/en not_active Ceased
- 2021-07-30 IL IL300245A patent/IL300245A/en unknown
- 2021-07-30 CN CN202180062049.8A patent/CN116234576A/zh active Pending
- 2021-07-30 EP EP21851080.8A patent/EP4188544A4/en active Pending
- 2021-07-30 CA CA3190474A patent/CA3190474A1/en active Pending
- 2021-07-30 AU AU2021316119A patent/AU2021316119A1/en active Pending
- 2021-07-30 KR KR1020237006832A patent/KR20230042744A/ko active Pending
- 2021-07-30 US US17/390,635 patent/US11912764B2/en active Active
- 2021-07-30 JP JP2023506315A patent/JP2023537316A/ja active Pending
-
2024
- 2024-01-17 US US18/415,511 patent/US20240309085A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023537316A (ja) | 2023-08-31 |
| EP4188544A4 (en) | 2024-09-11 |
| US20240309085A1 (en) | 2024-09-19 |
| US20220033492A1 (en) | 2022-02-03 |
| AU2021316119A1 (en) | 2023-03-02 |
| EP4188544A1 (en) | 2023-06-07 |
| CN116234576A (zh) | 2023-06-06 |
| US11912764B2 (en) | 2024-02-27 |
| CA3190474A1 (en) | 2022-02-03 |
| WO2022026914A1 (en) | 2022-02-03 |
| KR20230042744A (ko) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912764B2 (en) | Anti-connexin antibody formulations | |
| US11673967B2 (en) | Stabilized formulations containing anti-PCSK9 antibodies | |
| US10588976B2 (en) | Anti-CD40 antibody formulation | |
| US20260049132A1 (en) | Anti-connexin antibody formulations | |
| US20110070225A1 (en) | Beta antibody parenteral formulation | |
| KR20220124208A (ko) | 프로그램된 세포 사멸 수용체1 항체 제제 및 그 용도 | |
| US20170137535A1 (en) | Anti-factor d antibody formulations | |
| US12612466B2 (en) | Stabilized formulations containing anti-PCSK9 antibodies | |
| WO2024098180A1 (en) | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same | |
| HK40077586A (en) | Anto-connexin antibody formulations | |
| EP4548931A1 (en) | Anti-pcsk9 antibody preparation and use thereof | |
| US20230131324A1 (en) | Formulations of anti-endothelial lipase antibodies | |
| EP4615502A1 (en) | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same | |
| CN116887860A (zh) | 抗il5r抗体配制品 | |
| HK40103088A (zh) | 抗il5r抗体配制品 | |
| CN121490076A (zh) | 一种稳定的抗人masp2单克隆抗体制剂 | |
| HK40093811A (zh) | 高度浓缩的低粘度masp-2抑制性抗体制剂、试剂盒和方法 |